The Histamine H3 Receptor Antagonist DL77 Ameliorates MK801-Induced Memory Deficits in Rats

The role of Histamine H3 receptors (H3Rs) in memory, and the prospective of H3R antagonists in pharmacological control of neurodegenerative disorders, e.g., Alzheimer disease (AD) is well-accepted. For that reason, the procognitive effects of the H3R antagonist DL77 on cognitive impairments induced with MK801 were tested in an inhibitory passive avoidance paradigm (PAP) and novel object recognition (NOR) task in adult male rats, using donepezil (DOZ) as a standard drug. Acute systemic pretreatment with DL77 (2.5, 5, and 10 mg/kg, i.p.) significantly ameliorated memory deficits induced with MK801 in PAP (all P < 0.05, n = 7). The ameliorative effect of most promising dose of DL77 (5 mg/kg, i.p.) was reversed when rats were co-injected with the H3R agonist R-(α)-methylhistamine (RAMH, 10 mg/kg, i.p.) (p = 0.701 for MK801-amnesic group vs. MK801+DL77+RAMH group, n = 6). In the NOR paradigm, DL77 (5 mg/kg, i.p.) counteracted long-term memory (LTM) deficits induced with MK801 (P < 0.05, n = 6–8), and the DL77-provided effect was similar to that of DOZ (p = 0.788, n = 6–8), and was reversed when rats were co-injected with RAMH (10 mg/kg, i.p.) (p = 0.877, n = 6, as compared to the (MK801)-amnesic group). However, DL77 (5 mg/kg, i.p.) did not alter short-term memory (STM) impairment in NOR test (p = 0.772, n = 6–8, as compared to (MK801)-amnesic group). Moreover, DL77 (5 mg/kg) failed to modify anxiety and locomotor behaviors of animals innate to elevated-plus maze (EPM) (p = 0.67 for percentage of time spent exploring the open arms, p = 0.52 for number of entries into the open arms, p = 0.76 for percentage of entries into the open arms, and p = 0.73 number of closed arm entries as compared to saline-treated groups, all n = 6), demonstrating that the procognitive effects observed in PAP or NOR tests were unconnected to alterations in emotions or in natural locomotion of tested animals. These results signify the potential involvement of H3Rs in modulating neurotransmitters related to neurodegenerative disorders, e.g., AD.

[1]  M. Kermani,et al.  The effect of ghrelin on MK-801 induced memory impairment in rats , 2013, Peptides.

[2]  J. D. McGaugh,et al.  Drug enhancement of memory consolidation: historical perspective and neurobiological implications , 2008, Psychopharmacology.

[3]  Y. Lamberty,et al.  Histamine H3 antagonist thioperamide dose-dependently enhances memory consolidation and reverses amnesia induced by dizocilpine or scopolamine in a one-trial inhibitory avoidance task in mice , 2004, Behavioural Brain Research.

[4]  H. Stark,et al.  Cherry-picked ligands at histamine receptor subtypes , 2016, Neuropharmacology.

[5]  G. Coruzzi,et al.  The Histamine H3 Receptor , 2000 .

[6]  I. Weiner,et al.  SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodents , 2012, Pharmacology Biochemistry and Behavior.

[7]  Charles Bray.  The Physiology of the Brain , 1869 .

[8]  P. Blandina,et al.  Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H3 receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse , 2016, Neuropharmacology.

[9]  J. Arrang,et al.  Constitutive activity of the histamine H3 receptor. , 2007, Trends in pharmacological sciences.

[10]  R. Roesler,et al.  Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats , 2005, Behavioural Brain Research.

[11]  R. Andrew Chambers,et al.  The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia , 2009, Behavioural Brain Research.

[12]  J. Brioni,et al.  Discovery of histamine H 3 antagonists for the treatment of cognitive disorders and Alzheimer ’ s disease , 2010 .

[13]  P. Panula,et al.  Histamine and H3 Receptor in Alcohol-Related Behaviors , 2011, Journal of Pharmacology and Experimental Therapeutics.

[14]  H. Jaaro-Peled.  Gene models of schizophrenia: DISC1 mouse models. , 2009, Progress in brain research.

[15]  H. Stark,et al.  Azomethine prodrugs of (R)-alpha-methylhistamine, a highly potent and selective histamine H3-receptor agonist. , 2001, Current Medicinal Chemistry.

[16]  M. Giovannini,et al.  Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia , 1999, Behavioural Brain Research.

[17]  M. Bardgett,et al.  Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APPTg2576 mouse model of Alzheimer’s disease , 2011, Neurobiology of Learning and Memory.

[18]  B. Sadek,et al.  Thujone inhibits the function of α7-nicotinic acetylcholine receptors and impairs nicotine-induced memory enhancement in one-trial passive avoidance paradigm. , 2017, Toxicology.

[19]  J. Raber,et al.  Anxiety and cognition in female histidine decarboxylase knockout (Hdc −/−) mice , 2006, Behavioural Brain Research.

[20]  J. Raber,et al.  Sex- and Histamine-Dependent Long-Term Cognitive Effects of Methamphetamine Exposure , 2007, Neuropsychopharmacology.

[21]  D. Vohora,et al.  Beneficial interaction between clobenpropit and pyridoxine in prevention of electroshock-induced seizures in mice: Lack of histaminergic mechanisms , 2011, Human & experimental toxicology.

[22]  J. Schwartz,et al.  Autoregulation of histamine release in brain by presynaptic H3-receptors , 1985, Neuroscience.

[23]  K. Kieć‐Kononowicz,et al.  The novel non-imidazole histamine H3 receptor antagonist DL77 reduces voluntary alcohol intake and ethanol-induced conditioned place preference in mice , 2015, Physiology & Behavior.

[24]  S. Harusawa,et al.  Intracerebroventricular administration of histamine H3 receptor antagonists decreases seizures in rat models of epilepsia. , 2004, Methods and findings in experimental and clinical pharmacology.

[25]  D. Vohora,et al.  Histamine H3 receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectives , 2012, British journal of pharmacology.

[26]  B. Sadek,et al.  The dual-acting AChE inhibitor and H3 receptor antagonist UW-MD-72 reverses amnesia induced by scopolamine or dizocilpine in passive avoidance paradigm in rats , 2016, Physiology & Behavior.

[27]  D. Vohora,et al.  Histamine H3 receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice , 2014, Brain Research.

[28]  H. Yokoyama,et al.  The role of central histaminergic neuron system as an anticonvulsive mechanism in developing brain , 2001, Brain and Development.

[29]  Rob Leurs,et al.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors , 2015, Pharmacological Reviews.

[30]  T. Watanabe,et al.  Effect of thioperamide, a histamine H3 receptor antagonist, on electrically induced convulsions in mice. , 1993, European journal of pharmacology.

[31]  L Landais,et al.  BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, Hydrochloride], a Nonimidazole Inverse Agonist/Antagonist at the Human Histamine H3 Receptor: Preclinical Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[32]  R. Seifert,et al.  Histamine H(4) receptor-RGS fusion proteins expressed in Sf9 insect cells: a sensitive and reliable approach for the functional characterization of histamine H(4) receptor ligands. , 2009, Biochemical pharmacology.

[33]  Na Li,et al.  Effects of Xiaoyaosan on Stress-Induced Anxiety-Like Behavior in Rats: Involvement of CRF1 Receptor , 2016, Evidence-based complementary and alternative medicine : eCAM.

[34]  H. Haas,et al.  The physiology of brain histamine , 2001, Progress in Neurobiology.

[35]  M. Coumar,et al.  Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents. , 2016, European journal of medicinal chemistry.

[36]  Abdelkader Ennaceur,et al.  Effects of physostigmine and scopolamine on rats' performances in object-recognition and radial-maze tests , 1992, Psychopharmacology.

[37]  A. Ennaceur,et al.  A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs. non-spatial working memory , 1992, Behavioural Brain Research.

[38]  J. Schwartz,et al.  H3‐Receptors Control Histamine Release in Human Brain , 1988, Journal of neurochemistry.

[39]  E. Baldi,et al.  Histaminergic ligands injected into the nucleus basalis magnocellularis differentially affect fear conditioning consolidation. , 2013, The international journal of neuropsychopharmacology.

[40]  J. Witkin,et al.  Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. , 2004, Pharmacology & therapeutics.

[41]  J. Schwartz,et al.  Influence of imidazole replacement in different structural classes of histamine H(3)-receptor antagonists. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[42]  K. Kieć‐Kononowicz,et al.  The Histamine H3 Receptor Antagonist E159 Reverses Memory Deficits Induced by Dizocilpine in Passive Avoidance and Novel Object Recognition Paradigm in Rats , 2017, Front. Pharmacol..

[43]  V. Pascoli,et al.  H3 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing retrieval , 2008, Psychopharmacology.

[44]  S. Hogg.  A review of the validity and variability of the Elevated Plus-Maze as an animal model of anxiety , 1996, Pharmacology Biochemistry and Behavior.

[45]  B. Sadek,et al.  Anticonvulsant and procognitive properties of the non-imidazole histamine H3 receptor antagonist DL77 in male adult rats , 2016, Neuropharmacology.

[46]  S. File,et al.  The influence of open arm ledges and maze experience in the elevated plus-maze , 1996, Pharmacology Biochemistry and Behavior.

[47]  Y. Lamberty,et al.  The prototypical histamine H3 receptor inverse agonist thioperamide improves multiple aspects of memory processing in an inhibitory avoidance task , 2013, Behavioural Brain Research.

[48]  D. S. Nunes,et al.  MK801- and scopolamine-induced amnesias are reversed by an Amazonian herbal locally used as a “brain tonic” , 2008, Psychopharmacology.

[49]  J. Schwartz,et al.  Highly potent and selective ligands for histamine H3-receptors , 1987, Nature.

[50]  D. Bertrand,et al.  Tropisetron sensitizes α7 containing nicotinic receptors to low levels of acetylcholine in vitro and improves memory-related task performance in young and aged animals , 2017, Neuropharmacology.

[51]  I. Weiner,et al.  Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target , 2011, Pharmacology Biochemistry and Behavior.

[52]  G. Griebel,et al.  SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia , 2007, Neuropsychopharmacology.

[53]  J. Schwartz,et al.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor , 1983, Nature.

[54]  J. Schwartz,et al.  Properties and roles of the three subclasses of histamine receptors in brain. , 1986, The Journal of experimental biology.

[55]  J. Brioni,et al.  Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer's Disease , 2011, Journal of Pharmacology and Experimental Therapeutics.

[56]  E. Wei,et al.  Histamine ameliorates spatial memory deficits induced by MK-801 infusion into ventral hippocampus as evaluated by radial maze task in rats , 2005, Acta Pharmacologica Sinica.

[57]  E. Tirelli,et al.  The histamine H3-receptor inverse agonist Pitolisant improves fear memory in mice , 2013, Behavioural Brain Research.

[58]  J. Delacour,et al.  A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data , 1988, Behavioural Brain Research.

[59]  Nisachon Khunnawutmanotham,et al.  Synthesis and anti-acetylcholinesterase activity of scopoletin derivatives. , 2016, Bioorganic chemistry.

[60]  J. Rinne,et al.  Neuronal histamine deficit in Alzheimer's disease , 1997, Neuroscience.

[61]  P. Lestage,et al.  Effects of S 18986-1, a novel cognitive enhancer, on memory performances in an object recognition task in rats. , 2000, European journal of pharmacology.

[62]  Min Zhang,et al.  Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia. , 2013, The international journal of neuropsychopharmacology.

[63]  P. Doraiswamy.  Non-cholinergic strategies for treating and preventing Alzheimer's disease. , 2002, CNS drugs.

[64]  K. Browman,et al.  Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan , 2004, Behavioural Brain Research.

[65]  H. Stark,et al.  Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases , 2016, Behavioural Brain Research.

[66]  Stefan Offermanns,et al.  International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B) , 2011, Pharmacological Reviews.

[67]  I. Izquierdo,et al.  Histamine infused into basolateral amygdala enhances memory consolidation of inhibitory avoidance. , 2013, The international journal of neuropsychopharmacology.

[68]  C. Ballini,et al.  Regional Differential Effects of the Novel Histamine H3 Receptor Antagonist 6-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on Histamine Release in the Central Nervous System of Freely Moving Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.

[69]  M. Orsetti,et al.  Histamine H3-receptor antagonism improves memory retention and reverses the cognitive deficit induced by scopolamine in a two-trial place recognition task , 2001, Behavioural Brain Research.

[70]  K. Hashimoto,et al.  d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats , 2008, Behavioural Brain Research.

[71]  A. Sleight,et al.  5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism , 2004, Neuropharmacology.

[72]  J. Schwartz,et al.  Autoinhibition of histamine synthesis mediated by presynaptic H3-receptors , 1987, Neuroscience.

[73]  I. Izquierdo,et al.  Separate mechanisms for short- and long-term memory , 1999, Behavioural Brain Research.

[74]  J. Schwartz,et al.  Ether derivatives of 3-piperidinopropan-1-ol as non-imidazole histamine H3 receptor antagonists. , 2006, Bioorganic & medicinal chemistry.

[75]  C. Ferretti,et al.  Histamine H3-receptor blockade in the rat nucleus basalis magnocellularis improves place recognition memory , 2002, Psychopharmacology.

[76]  H. Haas,et al.  Histamine potentiates N-methyl-d-aspartate responses in acutely isolated hippocampal neurons , 1993, Neuron.

[77]  Michael Decker,et al.  The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats , 2016, Behavioural Brain Research SreeTestContent1.